The effects are similar on body mass index (BMI) (high level of evidence) and body weight (high level of evidence) in long-term follow-up.
Compared to treatment with GLP1 receptor antagonists (GLP1-RAs), MBS increases the percentage of patients achieving a sustainable weight reduction of 5% or 10% by around 27% and 51% in 2 years of follow-up (low level of evidence).
Compared to treatment as usual, MBS probably decreases total mortality by around 29%, cardiovascular mortality by around 53% and cardiovascular events by around 33% in 2-16 years of follow-up (moderate level of evidence).
In face-to-face comparisons, Roux-en-Y gastric bypass (RYGB) might be slightly more effective than sleeve gastrectomy (SE) in the reduction of BMI and weight loss (low level of evidence). However, in network meta-analysis, no clear superiority of one type of surgical procedure over the others was observed.
Comment: The meta-analysis «De Luca M, Zese M, Silverii GA, et al. Bariatric S...»1 did not report which medications were used, therefore some of the most recent studies on efficient medications might be lacking in the comparisons.
| Reference | Study type | Population | Intervention and comparison | Outcomes | Risk of bias «Additional comments for included studies...»2 |
|---|---|---|---|---|---|
| RCT=randomized controlled trial; with usual treatment SR=systematic review; MA=meta-analysis | |||||
| «De Luca M, Zese M, Silverii GA, et al. Bariatric S...»1 | MA including RCTs with a duration of at least 52 weeks | Altogether 65 trials (6 271 patients) including patients with overweight or obesity | Various metabolic and bariatric surgery (MBS) methods vs. lifestyle intervention (LSI), medical therapy (MT), both (LSI/MT) or another MBS method | Principal endpoint: BMI at the end of study period. Secondary endpoints: body weight, fat mass, percentage of weight loss, fasting plasma glucose, HbA1C, lipid profile, blood pressure, serious adverse events, mortality, diabetes remission, hypertension and dyslipidemia remission, quality of life, obstructive sleep apnea syndrome | Moderate |
| «Barrett TS, Hafermann JO, Richards S, et al. Obesi...»2 | Cohort study | 30458 patients (14101 with MBS, 16357 receiving GLP-1 RAs); mean age 50 years; 66.1% female | MBS (sleeve or gastric by-pass) vs. medication with GLP-1 receptor antagonist | Primary endpoints: The mean total costs per month at baseline and within the first and second year after index treatment, as well as the total costs over 2 years. Weight loss of 5% and 10% until the end of follow-up period. Secondary endpoints: Health care utilization and changes in the rates of obesity-related comorbidities at follow-up. |
High |
| «Sjöström L. Review of the key results from the Swe...»3 | Case-control study | Altogether 2010 patients with obesity who underwent MBS and 2037 patients with obesity | MBS (gastric bypass (13%), banding (19%), vertical banded gastroplasty (68%) versus matched controls receiving usual care | Primary endpoint: Mortality Secondary endpoints: Weight loss, cardiovascular disease, diabetes, biliary disease, quality of life and cost efficiency |
Moderate |
| Reference | Comments |
|---|---|
| «De Luca M, Zese M, Silverii GA, et al. Bariatric S...»1 | All trials were open-label. In several trials, the reporting of allocation, blinding
of assessors or attrition was inadequate. In addition, reporting bias and defects
in the randomization process could not be excluded in some of the studies. The mean follow-up time for all the studies included was 3.6 years (185.4 weeks,range: 52 to 520 weeks). |
| «Barrett TS, Hafermann JO, Richards S, et al. Obesi...»2 | The cohort study was based on electronic health records and conducted between 2018
and 2023. The data for the percentage of patients with sustained weight loss of 5
and 10% was available only for a small minority of the study population (1548 out
of 30458 patients). Patients treated with GLP1-RAs were older compared to patients treated with MBS, (mean age 49 yrs vs. 44 yrs). |
| «Sjöström L. Review of the key results from the Swe...»3 | Only the results for mortality and cardivascluar events are reported here. The control
group consisted of patients with obesity matched by gender, age, weight, height, waist
and hip circumferences, systolic blood pressure, serum cholesterol and triglyceride
levels, smoking status, diabetes, menopausal status, four psychosocial variables with
documented associations with the risk of death and two personality traits related
to treatment preferences. The control group's treatment varied from sophisticated lifestyle interventions and behavioral modification programs to, in many practices, no treatment at all. |
Results
| Reference | Number of studies and number of patients (I/C) | Follow-up time | Absolute number of events (%) I | Absolute number of events (%) C | Mean difference, kg/m2 (95% CI) |
|---|---|---|---|---|---|
| Level of evidence: high I= intervention; C=comparison; CI=confidence interval |
|||||
| «De Luca M, Zese M, Silverii GA, et al. Bariatric S...»1 | All trials: 20 (690/606) Patients with BMI > 34.9 kg/m2: 7 (182, 163) Trials enrolling only patients with BMI > 34.9 kg/m2: 8 (292, 221) |
52 weeks or more | All trials: -6.01 (-6.93 to -5.09) Patients with BMI > 34.9 kg/m2: -8.34 (-10.43to -6.25) Trials enrolling only patients with BMI > 34.9 kg/m2: -7.29 (-10.21 to -4,36) |
||
| Reference | Number of studies and number of patients (I/C) | Follow-up time | Absolute number of events (%) I | Absolute number of events (%) C | Mean difference, kg (95% CI) |
|---|---|---|---|---|---|
| Level of evidence: high I= intervention; C=comparison; CI=confidence interval |
|||||
| «De Luca M, Zese M, Silverii GA, et al. Bariatric S...»1 | 16 (536/448) | 52 weeks or more | -18.99 (-22.73 to -15.25) | ||
| Reference | Number of studies and number of patients (I/C) | Follow-up time | Absolute number of events (%) I | Absolute number of events (%) C | Relative effect, % (95% CI) |
|---|---|---|---|---|---|
| Level of evidence: high I= intervention; C=comparison; CI=confidence interval |
|||||
| «De Luca M, Zese M, Silverii GA, et al. Bariatric S...»1 | 13 (425,323) | 52 weeks or more | -17.70 (-14.54 to -20.87) | ||
| Reference | Number of studies and number of patients (I/C) | Follow-up time | Absolute number of events (%) I | Absolute number of events (%) C | Relative effect, % (95% CI) |
|---|---|---|---|---|---|
| Level of evidence: low The quality of evidence is downgraded due to very serious study limitations and upgraded due to large magnitude of the effect. |
|||||
| «Barrett TS, Hafermann JO, Richards S, et al. Obesi...»2 | 1 (1291, 257) | 2 years or more | 5% reduction: 1275 (98.8) 10% reduction: 1239 (96.0) |
5% reduction: 184 (71.6) 10% reduction: 118 (45.9) |
5% reduction: 27.2% (21.7 to 32.8) 10% reduction: 50.1% (43.9 to 56.3) |
| Reference | Number of studies and number of patients (I/C) | Follow-up time | Absolute number of events (%) I | Absolute number of events (%) C | Adjusted risk reduction, % (95% CI) |
|---|---|---|---|---|---|
| Level of evidence: moderate The quality of evidence is downgraded due to serious study limitations and upgraded due to large magnitude of the effect. |
|||||
| «Sjöström L. Review of the key results from the Swe...»3 | 1 (2001, 2027) | 2 to 16 years | Mortality: 101 (5.02) Total CVE: 199 (9.90) Fatal CVE: 28 (1.39) |
Mortality: 129 (6.33) Total CVE: 234 (11.49) Fatal CVE: 49 (2.40) |
Mortality: 29% (46 to 8) Total CVE: 33% (46 to 17) Fatal CVE: 53% (71 to 24) |
| Reference | Number of studies and number of patients (I/C) | Follow-up time | Absolute number of events (%) I | Absolute number of events (%) C | Mean difference (95% CI) |
|---|---|---|---|---|---|
| Level of evidence: low The quality of evidence is downgraded due to inconsistency (I2 85%, 83% and 91%) and imprecision. |
|||||
| «De Luca M, Zese M, Silverii GA, et al. Bariatric S...»1 | BMI: 16 (651/746) Body weight: Absolute:10 (399/396) Percentage: 11 (398/493) |
52 weeks or more | BMI: -1.30 (-2,45, -0,14) Body weight: Absolute -3,01 kg (-8,41, 2,39) Percentage: -4,80% (1,35, 8,26) |
||